Orgenesis Announces Cell-Based Vaccine Platform Targeting COVID-19 and other Existing and Emerging Viral Diseases
13 mai 2020 14h20 HE
|
Orgenesis Inc.
GERMANTOWN, Md., May 13, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering global biotech company committed to accelerating commercialization and...
Orgenesis First Quarter 2020 Revenue Increases 348% to $1.9 Million Reflecting Success of CGT Biotech Platform
11 mai 2020 07h30 HE
|
Orgenesis Inc.
GERMANTOWN, Md., May 11, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization and...
Orgenesis CEO Vered Caplan Recognized Among World's Top 20 Inspirational Leaders in Advanced Medicine in The Medicine Maker 'Power List 2020'
29 avr. 2020 10h32 HE
|
Orgenesis Inc.
GERMANTOWN, Md., April 29, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization and...
Orgenesis Completes Acquisition of Tamir Biotechnology, Inc. Assets Including Broad Spectrum Antiviral Platform
27 avr. 2020 07h30 HE
|
Orgenesis Inc.
GERMANTOWN, Md., April 27, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization and...
Orgenesis Announces Agreement to Acquire Assets of Tamir Biotechnology, Inc. Including Broad Spectrum Antiviral Platform
13 avr. 2020 07h45 HE
|
Orgenesis Inc.
GERMANTOWN, Md., April 13, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to lowering costs, accelerating...
Orgenesis Announces Joint Venture Agreement with RevaTis to Produce Muscle-Derived Mesenchymal Stem Cells (mdMSC) as a Source of Exosomes and Other Cellular Products for the Development of Related Therapies
08 avr. 2020 11h51 HE
|
Orgenesis Inc.
JV to utilize RevaTis’s patented technique to obtain mdMSCs through a minimally invasive muscle biopsy and leverage mdMSC manufacturing capability Plan to leverage Orgenesis’s autologous Cell and...
Orgenesis and ExcellaBio Announce Breakthrough Manufacturing Process for Bioxomes™, Proprietary Synthetic Exosomes/Extracellular Vesicles (EV)
31 mars 2020 07h30 HE
|
Orgenesis Inc.
GERMANTOWN, Md., March 31, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to lowering costs, accelerating...
Orgenesis CEO Vered Caplan Provides Letter to Shareholders
30 mars 2020 07h30 HE
|
Orgenesis Inc.
GERMANTOWN, Md., March 30, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to lowering costs, accelerating...
Orgenesis Provides Fiscal 2019 Year-End Results and Business Update; Outlines New Vertically Integrated Business Model and POCare Strategy Following Sale of Masthercell
10 mars 2020 07h30 HE
|
Orgenesis Inc.
Reports 78% increase in revenue and 92% increase in gross profit for fiscal 2019 Generated over $3.1 million in sales through POCare platform Rapidly expanding POCare platform through new...
Orgenesis Announces Collaboration with The John Hopkins University for the Development and Processing of Cell and Gene Based Clinical Therapeutics
19 févr. 2020 06h00 HE
|
Orgenesis Inc.
GERMANTOWN, Md., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS), a provider of point-of-care cell and gene therapy development, processing and treatment solutions (“POCare”), today...